ESMO President: What to watch for at ESMO 2021

Vaccinations in myeloma patients including for COVID-19

PrE0807: Neoadjuvant nivolumab without or with lirilumab in cisplatin-ineligible patients with muscle-invasive bladder cancer

CheckMate067 outcomes: Nivolumab plus ipilimumab in advanced melanoma

LEAP-004: Lenvatinib + pembrolizumab for patients with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor

Highlights from ASCO 2021

OncoAlert and ecancer ASCO roundup - Day 3

RELATIVITY-047: Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma

Phase III randomised trial comparing tebentafusp with investigator’s choice in first-line metastatic uveal melanoma

Adjuvant therapy with nivolumab combined with ipilimumab vs nivolumab alone in patients with resected stage IIIB-D/IV melanoma

Autologous tumour infiltrating lymphocytes cell therapy in metastatic non-small cell lung cancer

OncoAlert and ecancer weekly roundup for January 25 - 31, 2021